CYP2D6 rs11568818: Understanding the *10 Allele

What each genotype means

What is the rs11568818 Variant?

The rs11568818 variant is a single nucleotide polymorphism (SNP) located within the CYP2D6 gene on chromosome 22. In the context of pharmacogenomics, this specific SNP is a defining component of the CYP2D6*10 haplotype. The CYP2D6 gene is highly polymorphic, meaning it contains many variations that can alter the function of the protein it encodes. When researchers identify this specific SNP, they are often looking at the broader functional impact of the *10 allele. Because the CYP2D6 gene locus is complex, scientists often test for multiple SNPs to accurately assign a star allele status. While rs11568818 is a key marker, it is part of a larger genetic architecture that determines how an individual's liver enzymes metabolize various drugs. Understanding this variant requires looking at the gene as a whole, as the presence of this SNP is a strong indicator of the *10 allele's reduced functional capacity.

The Role of the CYP2D6 Gene

The CYP2D6 gene provides instructions for making an enzyme called cytochrome P450 2D6. This enzyme is primarily found in the liver and is responsible for breaking down, or metabolizing, a vast array of substances, including approximately 25% of all clinically used drugs. These include antidepressants, antipsychotics, beta-blockers, and certain pain medications. The enzyme acts like a chemical processor, converting these drugs into forms that the body can either use or eliminate. Because the CYP2D6 gene is so variable, different people have different versions of this enzyme. Some versions are highly efficient, while others, like the one associated with the *10 allele, have reduced activity. When an individual carries a variant that leads to reduced enzyme function, their body may process medications more slowly than expected. This can lead to higher concentrations of the drug in the bloodstream, potentially increasing the risk of side effects or requiring a dosage adjustment to achieve the desired therapeutic effect.

Research and Clinical Significance

Research into the CYP2D6*10 allele has established it as a 'decreased function' variant. Clinical studies have consistently shown that individuals carrying this allele exhibit lower enzyme activity compared to those with the fully functional *1 allele. This has significant implications for pharmacogenomics, the study of how genes affect a person's response to drugs. For example, in patients prescribed medications that require activation by the CYP2D6 enzyme, the *10 allele may result in reduced therapeutic efficacy. Conversely, for drugs that are deactivated by the enzyme, the *10 allele might lead to drug accumulation. The evidence strength for this association is considered moderate to strong in the scientific community, leading organizations like the Clinical Pharmacogenetics Implementation Consortium (CPIC) to provide guidelines for clinicians. It is important to note that while genetic associations are well-documented, they are only one factor in drug response. Other variables, such as age, liver health, and other medications, also play critical roles.

Population Frequency

The distribution of the CYP2D6*10 allele varies significantly across different global populations. It is most notably prevalent in East Asian populations, where it is often the most common variant allele, with frequencies reported between 40% and 50% in some studies. In contrast, this allele is found at much lower frequencies in European and African populations, where other variants like *2, *4, or *17 are more common. This variation highlights the importance of considering ancestry in pharmacogenomic research and clinical practice. Because the *10 allele is so common in East Asia, it is a primary focus for regional drug safety and dosing guidelines. Understanding these population-specific frequencies helps researchers and clinicians anticipate the prevalence of 'intermediate metabolizer' phenotypes in different communities, allowing for more personalized approaches to medication management. Genetic diversity is a fundamental aspect of human biology, and the high frequency of *10 in East Asia is a classic example of how specific genetic traits can become widespread within certain ancestral groups.

What You Can Do With This Information

If you have received genetic testing results indicating the presence of the CYP2D6*10 allele, it is important to view this information as a tool for conversation rather than a medical diagnosis. This genetic data provides insight into your potential metabolic profile, but it does not dictate your health outcomes. You should never make changes to your medication regimen based on genetic test results without consulting your healthcare provider. If you are currently taking a medication metabolized by CYP2D6, share your genetic report with your doctor or pharmacist. They can interpret these results in the context of your specific health history and current prescriptions. They may decide that no change is necessary, or they might consider adjusting your dosage or selecting an alternative medication. Always prioritize professional medical advice, as clinicians are trained to integrate genetic information with other clinical factors to ensure safe and effective treatment plans.

Frequently asked questions

Sources & further reading

Related variants in CYP2D6